Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlmirallWBO:ALM -0.91%85 EV-to-EBIT is 17.96 as of Aug. 05, 2026, which is 25% below its 10-year median of 24.04. GuruFocus rates WBO:ALM with a GF Score™ of 85/100 and a GF Value™ of €12.99. The stock has 2 warning signs investors should review. Among 690 Drug Manufacturers companies, Almirall ranks worse than 55.07% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Almirall's Enterprise Value for the quarter that ended in Jun. 2026 was €2,455 Mil.
Almirall's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €133 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Almirall EV-to-EBIT Related Terms
Almirall EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Almirall's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Almirall EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Almirall's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Almirall's EV-to-EBIT falls into.
Almirall's current Enterprise Value is €2,386 Mil.
Almirall's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €133 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Almirall (WBO:ALM) has a EV-to-EBIT of 17.96 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Almirall and its competitors. This is 25% below median its historical median of 24.04. According to the industry distribution chart, Almirall ranks #380 out of 690 companies in the Drug Manufacturers industry, placing it in the top 55.1%.
Is Almirall's EV-to-EBIT too high?
Almirall's current EV-to-EBIT of 17.96 is 25% below median its 10-year median of 24.04. The Drug Manufacturers industry median EV-to-EBIT is 15.57. Almirall's value of 17.96 is 15.4% above this industry median. Based on the distribution chart, Almirall ranks #380 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Almirall has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Almirall's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Almirall ranks #380 out of 690 companies for EV-to-EBIT. This places Almirall in the lower half of its industry. The industry median EV-to-EBIT is 15.57. Almirall's value of 17.96 is 15.4% above this benchmark. While the company's 10-year median is 24.04 vs. the industry median of 15.57, Almirall has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.57, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Almirall's current EV-to-EBIT of 17.96 is 15.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Almirall and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Almirall's current EV-to-EBIT is 17.96, which is 25% below median its own 10-year median of 24.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Almirall stock overvalued right now?
Almirall (WBO:ALM) has a current EV-to-EBIT of 17.96. The stock's GF Value™ is €12.99, compared to a current price of €10.94 — trading 15.8% below its estimated fair value. The current EV-to-EBIT is 17.96, which is 25% below median its 10-year median of 24.04 and 15.4% above the Drug Manufacturers industry median of 15.57. Almirall's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Almirall (WBO:ALM), the current EV-to-EBIT is 17.96 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Almirall (WBO:ALM) Overvalued in 2026?
Based on GuruFocus' analysis, Almirall stock appears to be undervalued.
The current stock price of €10.94 is trading 15.8% below its estimated GF Value™ of €12.99.
Key valuation signals for WBO:ALM:
EV-to-EBIT: 17.96 (25% below median its 10-year median of 24.04)
GF Value™: €12.99 vs. price of €10.94 (15.8% below fair value)
Industry Position: 15.4% above the Drug Manufacturers median (#380 of 690)
No single metric tells the full story. See the WBO:ALM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Almirall SA is a skin-health focused pharmaceutical company based in Barcelona and the parent company of a group engaged in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as related raw materials. The Group applies science to provide medical solutions focused on skin health diseases and partners with healthcare professionals, and its activities also include cosmetics; chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use; instruments and accessories for the chemical, pharmaceutical and clinical industry; and research on active chemical and pharmaceutical ingredients and products.
85GF Score
Get the complete analysis for WBO:ALM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ALM has been successfully added to your 
